 ImmunityBio and NantKwest have merged, creating a juggernaut pre-clinical and clinical pipeline. The share price has been weak since the merger, however I remain bullish at these prices. The company has an impressive COVID-19 vaccine candidate that could be best-in-class and possibly help end the pandemic. 